ARVINAS, INC. (ARVN)
$9.18-$0.06 (-0.65%) Today
Randy Teel - OfficerAndrew Saik - OfficerRandy Teel - OfficerArvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 8,272 | $66K |
| Grant or award | 12 | 229,446 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
34 Form 4 filings on record, the earliest from Nov 12, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Alsup Laurie Smaldone - Director | Grant or award | Common Stock | 15,527 | $0.00 | - | |
| Alsup Laurie Smaldone - Director | Grant or award | Stock Option (right to buy) | 22,714 | $0.00 | - | |
| Leslie V. Norwalk - Director | Grant or award | Stock Option (right to buy) | 22,714 | $0.00 | - | |
| Leslie V. Norwalk - Director | Grant or award | Common Stock | 15,527 | $0.00 | - | |
| Briggs Morrison - Director | Grant or award | Common Stock | 15,527 | $0.00 | - | |
| Briggs Morrison - Director | Grant or award | Stock Option (right to buy) | 22,714 | $0.00 | - | |
| Edward Moore Kennedy Jr. - Director | Grant or award | Common Stock | 15,527 | $0.00 | - | |
| Edward Moore Kennedy Jr. - Director | Grant or award | Stock Option (right to buy) | 22,714 | $0.00 | - | |
 Everett Cunningham - Director | Grant or award | Stock Option (right to buy) | 22,714 | $0.00 | - | |
| Everett Cunningham - Director | Grant or award | Common Stock | 15,527 | $0.00 | - | |
 Linda Bain - Director | Grant or award | Common Stock | 15,527 | $0.00 | - | |
| Linda Bain - Director | Grant or award | Stock Option (right to buy) | 22,714 | $0.00 | - | |
| Andrew Saik - Officer | Open-market sale | Common Stock | 5,696 | $8.16 | $46K | |
| Angela M. Cacace - Officer | Open-market sale | Common Stock | 2,576 | $7.60 | $20K | |
| Randy Teel - Officer | Open-market sale | Common Stock | 2,209 | $9.04 | $20K | |
| Andrew Saik - Officer | Open-market sale | Common Stock | 11,139 | $9.94 | $111K | |
| David K. Loomis - Officer | Open-market sale | Common Stock | 1,919 | $9.94 | $19K | |
| Angela M. Cacace - Officer | Open-market sale | Common Stock | 9,657 | $9.94 | $96K | |
| Noah Berkowitz - Officer | Open-market sale | Common Stock | 11,108 | $9.94 | $110K | |
| Randy Teel - Officer | Open-market sale | Common Stock | 9,657 | $9.94 | $96K | |
| Noah Berkowitz - Officer | Open-market sale | Common Stock | 6,435 | $11.10 | $71K | |
| Randy Teel - Officer | Grant or award | Common Stock | 147,179 | $0.00 | - | |
| Briggs Morrison - Director | Open-market purchase | Common Stock | 20,000 | $13.40 | $268K | |
| David K. Loomis - Officer | Grant or award | Common Stock | 12,420 | $0.00 | - | |
| David K. Loomis - Officer | Grant or award | Stock Option (right to buy) | 18,504 | $0.00 | - | |
| Angela M. Cacace - Officer | Grant or award | Common Stock | 45,000 | $0.00 | - | |
| Angela M. Cacace - Officer | Grant or award | Stock Option (right to buy) | 67,000 | $0.00 | - | |
| Noah Berkowitz - Officer | Grant or award | Common Stock | 45,000 | $0.00 | - | |
| Noah Berkowitz - Officer | Grant or award | Stock Option (right to buy) | 67,000 | $0.00 | - | |
| Andrew Saik - Officer | Grant or award | Common Stock | 45,000 | $0.00 | - | |
| Andrew Saik - Officer | Grant or award | Stock Option (right to buy) | 67,000 | $0.00 | - | |
| Randy Teel - Officer | Grant or award | Common Stock | 147,791 | $0.00 | - | |
| Randy Teel - Officer | Grant or award | Stock Option (right to buy) | 218,691 | $0.00 | - | |
| John G. Houston - Director | Open-market sale | Common Stock | 4,688 | $13.24 | $62K | |
| John G. Houston - Director | Open-market sale | Common Stock | 18,822 | $13.24 | $249K | |
| John G. Houston - Director | Open-market sale | Common Stock | 11,787 | $13.14 | $155K | |
| David K. Loomis - Officer | Open-market sale | Common Stock | 1,108 | $12.16 | $13K | |
| Angela M. Cacace - Officer | Open-market sale | Common Stock | 1,038 | $12.16 | $13K | |
| Angela M. Cacace - Officer | Open-market sale | Common Stock | 2,571 | $12.16 | $31K | |
| Randy Teel - Officer | Open-market sale | Common Stock | 1,038 | $12.16 | $13K | |
| Randy Teel - Officer | Open-market sale | Common Stock | 3,748 | $12.16 | $46K | |
| Randy Teel - Officer | Open-market sale | Common Stock | 4,403 | $11.89 | $52K | |
| Andrew Saik - Officer | Open-market sale | Common Stock | 5,134 | $11.89 | $61K | |
| Angela M. Cacace - Officer | Open-market sale | Common Stock | 4,592 | $11.89 | $55K | |
| Noah Berkowitz - Officer | Open-market sale | Common Stock | 5,685 | $11.89 | $68K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| NOAH C BERKOWITZ | Officer | 30,000 | $264K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
ARVINAS, INC. (ARVN) had 8 insider filings in the last 90 days, with the most recent on 2026-06-26. The full record for ARVN runs to 34 Form 4 filings, the earliest from 2024-11-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ARVN were filed in the last 90 days. 2 purchases are on record for this company.
2 insider sales of ARVN were filed in the last 90 days, totaling $66K.
This page tracks ARVN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ARVN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
